Ken Griffin Immix Biopharma, Inc. Put Options Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
Put Options
2 transactions
Others Institutions Holding IMMX
# of Institutions
29Shares Held
3.33MCall Options Held
11.5KPut Options Held
900-
Bleichroeder LP New York, NY850KShares$1.66 Million0.6% of portfolio
-
Cable Car Capital LLC San Francisco, CA796KShares$1.55 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA699KShares$1.36 Million0.0% of portfolio
-
Lynwood Capital Management Inc.405KShares$789,75011.13% of portfolio
-
Geode Capital Management, LLC Boston, MA150KShares$292,6590.0% of portfolio
About Immix Biopharma, Inc.
- Ticker IMMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,910,100
- Market Cap $27.1M
- Description
- Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specif...